An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Tuberculosis Clinical Trial

— NEXT  

Official title:

Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02454205
• Other study ID #: NExT-5001
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: November 12, 2015
• Est. completion date: August 30, 2021

Study information

• Verified date: September 2021
• Source: University of Cape Town
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the impact of a new injection-free six-to-nine month treatment regimen of linezolid, bedaquiline, levofloxacin, pyrazinamide (PZA) and ethionamide/high dose isoniazid (INH) compared to the conventional empiric injection-based regimen. The secondary aim is to determine if other treatment-related outcomes including adverse events, adherence to treatment, culture conversion, and cure/completion are significantly different in the intervention and conventional arms.

Description:

Background:

TB is completely out of control in South Africa and is now officially the most common cause of death in this country. Alarmingly, the gravity if this pandemic has now been compounded by the emergence of multidrug-resistant TB (MDR-TB), which constitutes resistance to the two most potent anti-tuberculous drugs, namely rifampicin and isoniazid . XDR-TB refers to resistance to rifampicin, isoniazid, any fluoroquinolone, and any second line injectable drug (amikacin, kanamycin, or capreomycin). MDR-TB is a burgeoning epidemic in South Africa, with rates trebling over the last decade. It is of considerable concern because mortality is high (up to 50% in South Africa) and it often affects economically active young adults. It is also a major threat to health care workers in South Africa. We recently showed a rate in SA health care workers 6 fold higher than the general population further exacerbating the shortage of this critical workforce in the country. The increasing cost to manage this disease is unsustainable.

Although drug-resistant TB comprises less than 2% of the total caseload in the country (approximately ½ million patients with TB treated per year), it consumes almost 40% of the total national TB programme budget, and more than 60% of the total TB drug budget. This is not sustainable and drug-resistant TB therefore has the capacity to destabilise functional TB control programmes in many countries in Africa.

The treatment of MDR-TB is arduous, with a six to eight month intensive phase of daily painful injections of Kanamycin combined with oral pyrazinamide, a fluoroquinolone (moxifloxacin or levofloxacin), prothionamide and either cycloserine or para-aminosalicylic acid (if cycloserine cannot be used). Treatment continues for 18 months after consecutive negative sputum cultures, and lasts at least 20 months. There are substantial drug-associated toxicities and adverse events that frequently lead to interruption or cessation of treatment.

This study proposes to test the efficacy of a new drug regimen for the treatment of MDR-TB which is of short term duration and which does not contain an injectable drug, thus making treatment easier to administer and thereby potentially increasing compliance. All the drugs will be available to the NTP if the study is shown to be successful. This regimen will comprise linezolid, bedaquiline, levofloxacin, PZA and either ethionamide or high dose INH or teridazone. A gene-directed diagnostic approach (mutational analysis) will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. If both mutations are present then to administer teridazone.

Furthermore, in the proposed study the key aim is to test a regimen (rather than an individual drug) and will look at how the outcomes (24 month), including treatment completion/cure (i.e. treatment success which is the primary outcome) and mortality, are impacted. It is expected that introduction of a shortened effective regimen will reduce drop out and drastically reduce mortality and on-going transmission. Moreover, the rates of XDR-TB and TDR-TB may also decline.

The study will be conducted at 5 trial sites in South Africa that are designated MDR-TB treatment facilities and it many cases patients will be recruited from the satellite clinics of these centres reflecting the decentralized MDR-TB program. All the sites have the necessary expertise and facilities to carry out the proposed study. The study is a fully conceived and funded within South Africa.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 154
• Est. completion date: August 30, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Newly diagnosed culture and/or GeneXpert positive pulmonary TB.

• Rifampicin resistance detected using at least two susceptibility testing assays (GeneXpert, HainMTBDRplus or phenotypic) using a sputum sample during screening.

• Provide written informed consent prior to all trial-related procedures including HIV testing.

• Male or female aged 18 years and older.

• Body weight between 40 and 90 kg, inclusive.

• Women of non-childbearing potential or participants of either sex who are using or willing to use effective methods of birth control

Exclusion Criteria:

• A participant who in the opinion of the investigator is unlikely to cope with regular visits to the trial site either because of travel constraints, or because of drug or alcohol abuse, or other reason.

• Known at screening to have XDR-TB or pre-XDR-TB (i.e. fluoroquinolone or second-line injectable drug (SLID) resistance i.e. to capreomycin, amikacin and kanamycin).

• Previous history of treatment for MDR-TB or XDR-TB or previous treatment with bedaquiline.

• Currently on MDR-TB treatment for more than 2 weeks.

• Any participant with a Karnofsky score < 50.

• Known allergy to any of the trial drugs or related substances.

• Having participated in other clinical studies within 8 weeks prior to trial start where investigational agents were used that may potentially impact current trial outcome.

• Presence (or evidence) of symptomatic neuropathy grade 3 or higher.

• Epilepsy where drugs prolonging QT interval are used.

• Participant who is pregnant, breast-feeding (and not willing to stop), or planning to conceive a child within 6 months of cessation of treatment.

• Incompatibility between microbiological and clinical/ radiological findings (i.e. where the clinical and/or radiological findings are discordant with microbiological testing suggesting laboratory contamination).

• Participants with ECG abnormalities, in particular QT prolongation.

• Any pre-existing laboratory abnormality which in the opinion of the investigator will place the participant at risk. Patients with any of the following baseline laboratory abnormalities will be excluded from the study:

• Creatinine grade 2 or worse (>1.4 times ULN)

• Hemoglobin level grade 4 (HB <6.5g/dL)

• Platelets grade 3 or worse (<49999 x 109/L)

• ALT grade 3 or worse (>5 times ULN)

• Total bilirubin grade 3 or worse (>2.5 times ULN)

• Specific prior or concurrent medication/treatments (see Restrictions section below, Table 3).

• Rifampicin monoresistant TB.

• Fluoroquinolone and/or SLID resistance. Although in South Africa, the standard of care does not single out MDR-TB with fluoroquinolone or aminoglycoside resistance at initiation of MDR-TB treatment, in this study the Hain MTBDRsl LPA will be used on the sputum sample to exclude any pre-XDR and XDR cases from participation in the study (results from the LPA and phenotypic DST testing on the isolate will be available 3-6 weeks later).

All inclusion and no exclusion criteria must be met prior to enrolment and randomisation. Whenever the investigator has reason to suspect that there might be a health problem (other than TB) participation should only be considered after discussing the case with the medical monitor. Note: Participants who are currently on, or have previously been on drug-sensitive TB treatment are not excluded from participation.

Post-randomisation exclusion criteria:

• Fluoroquinolone and/or SLID resistance detected on DST using the isolate. Note: A woman who falls pregnant during the treatment phase of the trial will not be excluded but will be counselled regarding potential termination of pregnancy.

Related Conditions & MeSH terms

• Extensively Drug-Resistant Tuberculosis
• Extensively-drug Resistant Tuberculosis
• Multidrug Resistant Tuberculosis
• Tuberculosis
• Tuberculosis, Multidrug-Resistant

Intervention

Drug:
• Linezolid
600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
• Bedaquiline
400mg po daily for 2 weeks, followed by 200mg three times per week .
• Levofloxacin
750mg (<50kg) 1000mg (>50kg)
• Pyrazinamide
1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
• Isoniazid
high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
• Ethionamide
15mg/kg (max 900mg)
• Terizidone
750mg (40-70kg) 750-1000mg (71-90kg)
• Moxifloxacin
400mg po daily.
• Kanamycin
500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.

Locations

Country	Name	City	State
South Africa	Brooklyn Chest Hospital	Cape Town	Western Cape

Sponsors (5)

Lead Sponsor	Collaborator
University of Cape Town	University of Cape Town Lung Institute, University of Limpopo, University of Stellenbosch, Walter Sisulu University

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment success	In the conventional arm treatment success is defined as the sum of cured or treatment completed cases. In the intervention arm treatment success is defined as the sum of cured and treatment completed cases, without subsequent relapse, re-infection or death during the 15-18 month follow up period.	24 months after initiation of treatment in either arm.
Secondary	Favourable outcome rate		At 6-9 months for the intervention arm and 21-24 months for the conventional arm.
Secondary	Time specific rate of treatment failure.		6-36 months
Secondary	Time specific culture conversion proportions and rates.		6-36 months
Secondary	Time specific relapse rate.		6-36 months.
Secondary	Rate of re-infection.		6-36 months.
Secondary	All cause mortality		0-36 months.
Secondary	Composite measure of QT interval on ECG, grade 3 and 4 adverse events, stopping drugs Safety and tolerability end-points.		0-36 months.
Secondary	Default rate	Rate at which participants interrupt treatment for two or more consecutive months for any reason without medical approval.	2-24 months
Secondary	Rate of loss of follow-up.	Rate at which a participant becomes untraceable at any point in the study, and remains untraceable at completion of study despite every effort being made by researchers to locate the participant.	0-36 months.

External Links

•   Home page of the Lung Institute